lyophilization raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-06 and is reviewed periodically as new material appears.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
However, some studies have also shown that malolactic fermentation may diminish primary fruit aromas such as Pinot noir, often losing raspberry and strawberry notes after MLF. Additionally, red wines may endure a loss of color after MLF due to pH changes that causes a shift in the equilibrium of the anthocyanins which contribute to the stability of color in wine.
== Substrates == So far, more than 150 proteins have been identified to be targets for CK1-mediated phosphorylation, at least in vitro. Phosphorylation of numerous substrates is enabled due to the existence of several consensus motifs, which can be recognized by CK1 isoforms.
=== Lipid changes === Spironolactone has been found to increase LDL ("bad") cholesterol and decrease HDL ("good") cholesterol levels at the relatively high doses used in women with polycystic ovary syndrome. As such, it may have unfavorable effects on the blood lipid profile in this context. Heightened LDL cholesterol levels are a potential risk factor for cardiovascular disease, such as atherosclerosis or coronary heart disease. Consequently, spironolactone probably should not be given to women with dyslipidemia (e.g., high cholesterol). Unfavorable lipid changes have also been seen with other antiandrogens, such as cyproterone acetate and bicalutamide.
=== 13 May === Moments before Ukraine's entry to the Eurovision Song Contest 2023, Tvorchi, were due to perform in Liverpool in the United Kingdom, their hometown of Ternopil was struck by Russian missiles, injuring two people and damaging warehouses. This prompted them to close their performance with a message for solidarity with Ukraine. 11 people were also injured in overnight drone attacks in Khmelnytskyi. The Ukrainian military said that 18 out of 22 Iranian Shahed-131/136 drones were shot down in the attacks. Russia accused Ukraine of attacking the occupied city of Luhansk with its newly acquired British Storm Shadow missiles, wounding six children. It also claimed to have downed two Ukrainian aircraft, an Su-24 and a MiG-29, that launched the missiles. The Russian Defence Ministry said that Russian forces had seized a block in Bakhmut. Two Russian helicopters, both Mi-8s, and two Russian fighters, an Su-34 and an Su-35, crashed in Bryansk Oblast, near the border with Ukraine with no survivors. Nine personnel were said to have been killed. The Russian newspaper Kommersant reported that the aircraft were on their way for a bombing run in neighboring Chernihiv Oblast when they were shot down by Ukrainian forces, which was also echoed by Russian pro-military bloggers. The Russian state news agency TASS only reported the loss of an Su-34 warplane without providing a reason, as well as that of a helicopter due to an engine fire near Klintsy, about 40 km (25 mi) from the international border.
=== FORTUNE, Modern Healthcare and Press Ganey awards === Southern Ohio Medical Center has been recognized as one of FORTUNE Magazine’s Best Places to Work in America for six straight years. In 2013, it came in 29th on the list with FORTUNE noting: “Employees are proud to work for a medical provider that has won numerous awards for patient care, a fact that's reflected in its average tenure. Nearly 20% of the staff has worked there for more than 20 years.” SOMC was recognized on the FORTUNE list again in 2014 (coming in 18th) and 2015 (coming in 44th). In the 2015 survey, 93% of SOMC employees described their workplace as "a great place to work." Modern Healthcare Magazine also recognized SOMC as one of the nation's best healthcare employers in 2010, 2011 and 2012. In 2012, Southern Ohio Medical Center was one of only 13 Press Ganey clients in the nation to be chosen as a Distinctive Workplace Award winner. The award was given to organizations that reached, and sustained, the 95th percentile in employee satisfaction – SOMC was at the 99th percentile.
Sources: en.wikipedia.org
=== Tooth decay === The WHO, Action on Sugar and the Scientific Advisory Committee on Nutrition (SACN) state dental caries, also known as tooth decay/cavities, "can be prevented by avoiding dietary free sugars". A review of human studies showed that the incidence of caries is lower when sugar intake is less than 10% of total energy consumed. Sugar-sweetened beverage consumption is associated with an increased risk of tooth decay.
29 July – Prime Minister Rishi Sunak urges Mayor of London Sadiq Kahn to reconsider his plans to expand the Ultra Low Emission Zone, describing it as an "unnecessary extra tax". 30 July – Grime artist Stormzy and HSBC announce an extension of the Stormzy Scholarships scheme, with funding for a further 36 places for black students at Cambridge University. Each student will receive a £20,000 annual scholarship. 31 July – The National Education Union says that its members have voted to accept the UK government's 6.5% pay offer for teachers in England, with 86% of those voting in favour of the increase. Wild camping is to be allowed on Dartmoor once again after the National Park Authority wins a legal challenge against its suspension.
== References == Ladisch, Michael R. (2001). Bioseparations Engineering: Principles, Practice, and Economics. Wiley. ISBN 0-471-24476-7. Harrison, Roger G.; Paul W. Todd; Scott R. Rudge; Demetri Petrides (2003). Bioseparations science and engineering. Oxford University Press. ISBN 0-19-512340-9. Krishna Prasad, Nooralabettu (2010). Downstream Processing-A New Horizone in Biotechnology. Prentice Hall of India Pvt. Ltd, New Delhi. ISBN 978-81-203-4040-4.
The ICRU and ICRP specify differently defined weighting factors that apply to environmental measurements (quality factor) and body-related dose equivalent data (radiation weighting factor). In relation to the body, the relevant dose term is the Organ Equivalent Dose (formerly "Organ Dose"). This is the dose equivalent averaged over an organ. Multiplied by organ-specific tissue weighting factors and summed over all organs, the effective dose is obtained, which represents a dose balance. In relation to environmental measurements, the ambient dose equivalent or local dose is relevant. Its increase over time is called the local dose rate. Even at very low effective doses, stochastic effects (genetic and cancer risk) are expected. At effective doses above 0.1 Sv, deterministic effects also occur (tissue damage up to radiation sickness at very high doses). Correspondingly high radiation doses are now only given in units of Gy. Natural radiation exposure in Germany, with an annual average effective dose of about 0.002 Sv, is well below this range.
High Voltage Engineering Corporation accelerators originated with the electrostatic generator designed by MIT physicist Robert J. Van de Graaff. In an effort to split the atom, Van de Graaff devised a electrostatic method to accelerate and direct charged particles at high voltages. While constructing a high-voltage prototype accelerator in the early 1930s, Van de Graaff patented several technologies that would form part of the future company's technology base. MIT professor John G. Trump, an apprentice of Van de Graaff, focused on making the generators useful for cancer radiotherapy. In the 1930s, few hospitals could afford radium sources, available x-ray sources were insufficiently powerful, and both methods damaged healthy tissues. Trump proposed that the unlimited, controllable beam output of Van de Graaff devices could make treatment affordable and safer. He built a series of compact "supervoltage" (>1-megavolt) x-ray generators for local cancer hospitals and secured further patents for the smaller generators. Returning from his World War II leave, Trump received requests from several British hospitals for new cancer generators and decided a company could better fulfill further orders. He recruited Van de Graaff to serve as co-founder and chief scientist. Neither professor wished to leave MIT, so Trump brought in British physicist Denis M. Robinson as a third co-founder and president. In 1946, Trump approached his wartime colleague, MIT President Karl Compton, about supporting the venture.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.